MyCellHub is participating in the RHYTHMS project, a groundbreaking Eurostars initiative that will transform how cell therapies are manufactured globally. Working alongside leading partners Scinus Cell Expansion, Stemmatters, and Skåne University Hospital, we're developing cutting-edge software solutions to enable high-quality, decentralized cell therapy production.

MyCellHub’s Role: Pioneering Smart Manufacturing Software

MyCellHub is developing two revolutionary modules that will become integral parts of our platform:

Decentralised Equipment Management Module: Our first deliverable creates a comprehensive solution for managing cell therapy manufacturing across multiple sites. This adaptation to our cloud-based system will provide real-time monitoring and control of cell culture equipment, ensuring consistent manufacturing standards wherever production is done. By centralizing equipment data while enabling distributed manufacturing, we're solving one of the industry's biggest challenges: maintaining GMP compliance across decentralized operations.

Process Analytical Technology (PAT) Module: Building on our expertise in bioprocess data analytics, we're developing intelligent software that automatically identifies critical process parameters and is able to control manufacturing in real-time. This module will integrate seamlessly with advanced sensor technology to provide unprecedented insight into cell culture conditions, enabling automated adjustments that ensure consistent, high-quality outcomes.

Transforming Cell Therapy Access

The RHYTHMS toolkit addresses a critical healthcare challenge: while cell therapies show tremendous promise for treating cancer, autoimmune diseases, and degenerative conditions, current centralized manufacturing creates bottlenecks that limit patient access and increase costs. Our software solutions will enable hospitals and specialized centers to manufacture these life-saving therapies closer to patients, reducing logistics complexity and treatment delays.

This project perfectly aligns with MyCellHub's mission to democratize advanced manufacturing through intelligent software. By combining our proven GMP-compliant platform with these new capabilities, we're not just advancing technology, we're helping bring personalized medicine within reach of patients worldwide.

RHYTHMS is supported by Eurostars, part of the European Partnership on Innovative SMEs, co-funded by the European Union through Horizon Europe and is executed with the support of VLAIO.

‍